Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (51-60 of 138) with videos related to

Pageof 14
Sort By:
Acta Haematologica|May 27, 2009
Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alphaOlga A Tsopra, Panos G Ziros, Eleni D Lagadinou, et al.
International Journal of Cancer|January 17, 2019
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaEvangelos Terpos, Eirini Katodritou, Argiris Symeonidis, et al.
Hemoglobin|May 2, 2019
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort StudyAlexandra Kolliopoulou, Stavroula Siamoglou, Anne John, et al.
American Journal of Hematology|February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIAEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Human Genomics|April 25, 2023
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment responseStavroula Siamoglou, Ruben Boers, Maria Koromina, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 27, 2015
Efficacy of Interferon A-2b monotherapy in Β-thalassemics with chronic hepatitis CMaria Kalafateli, Alexandra Kourakli, Nikolaos Gatselis, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 17, 2019
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)Ioannis Kotsianidis, Sotirios G Papageorgiou, Vassiliki Pappa, et al.
European Journal of Haematology|May 19, 2010
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agentsEvangelos Terpos, Eirini Katodritou, Maria Roussou, et al.
Leukemia & Lymphoma|October 8, 2024
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratificationStavroula Syriopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, et al.
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Pageof 14

Showing results (51-60 of 138) with videos related to

Sort By:
Pageof 14
Acta Haematologica|May 27, 2009
Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alphaOlga A Tsopra, Panos G Ziros, Eleni D Lagadinou, et al.
International Journal of Cancer|January 17, 2019
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaEvangelos Terpos, Eirini Katodritou, Argiris Symeonidis, et al.
Hemoglobin|May 2, 2019
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort StudyAlexandra Kolliopoulou, Stavroula Siamoglou, Anne John, et al.
American Journal of Hematology|February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIAEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Human Genomics|April 25, 2023
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment responseStavroula Siamoglou, Ruben Boers, Maria Koromina, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 27, 2015
Efficacy of Interferon A-2b monotherapy in Β-thalassemics with chronic hepatitis CMaria Kalafateli, Alexandra Kourakli, Nikolaos Gatselis, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 17, 2019
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)Ioannis Kotsianidis, Sotirios G Papageorgiou, Vassiliki Pappa, et al.
European Journal of Haematology|May 19, 2010
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agentsEvangelos Terpos, Eirini Katodritou, Maria Roussou, et al.
Leukemia & Lymphoma|October 8, 2024
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratificationStavroula Syriopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, et al.
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Pageof 14